Literature DB >> 16274239

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.

Kristin B Whitson1, Stefanie R Whitson, Monica L Red-Brewer, Austin J McCoy, Angela A Vitali, Francesca Walker, Terrance G Johns, Albert H Beth, James V Staros.   

Abstract

We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR). Our previous study showed that the population of cell-surface expressed EGFRs in A431 cells, a human epidermoid carcinoma cell line, is composed of two subpopulations that differ by glycosylation at N(579) [Zhen et al. (2003) Biochemistry 42, 5478-5492]. To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). However, ligand drives the majority of N579Q-EGFR dimerization, suggesting that untethering, while necessary, is not sufficient to drive dimerization. Ligand-binding experiments reveal a much greater fraction of N579Q-EGFRs in a high-affinity state compared to the fraction of WT-EGFRs in a high-affinity state. However, differences in the kinetic association and dissociation rates indicate that the high-affinity states of the WT and the N579Q receptors are distinct. EGF-stimulated phosphorylation in cells expressing N579Q-EGFRs results in notable differences in the pattern of tyrosine phosphorylated proteins compared with that obtained in cells expressing WT-EGFRs. Moreover, although WT-EGFRs confer cell survival in 32D cells in the absence of interleukin-3 and EGF, we found that receptors lacking glycosylation at N(579) do not. This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274239     DOI: 10.1021/bi050751j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.

Authors:  Hsin-Yung Yen; Ying-Chih Liu; Nai-Yu Chen; Chia-Feng Tsai; Yi-Ting Wang; Yu-Ju Chen; Tsui-Ling Hsu; Pan-Chyr Yang; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-13       Impact factor: 11.205

Review 3.  A structural perspective on the regulation of the epidermal growth factor receptor.

Authors:  Erika Kovacs; Julie Anne Zorn; Yongjian Huang; Tiago Barros; John Kuriyan
Journal:  Annu Rev Biochem       Date:  2015-01-26       Impact factor: 23.643

4.  Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry.

Authors:  Christopher J Tynan; Selene K Roberts; Daniel J Rolfe; David T Clarke; Hannes H Loeffler; Johannes Kästner; Martyn D Winn; Peter J Parker; Marisa L Martin-Fernandez
Journal:  Mol Cell Biol       Date:  2011-03-28       Impact factor: 4.272

5.  Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.

Authors:  Ying-Chih Liu; Hsin-Yung Yen; Chien-Yu Chen; Chein-Hung Chen; Ping-Fu Cheng; Yi-Hsiu Juan; Chung-Hsuan Chen; Kay-Hooi Khoo; Chong-Jen Yu; Pan-Chyr Yang; Tsui-Ling Hsu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 6.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

7.  Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding.

Authors:  Eric S Taylor; Laercio Pol-Fachin; Roberto D Lins; Steven K Lower
Journal:  Proteins       Date:  2017-01-18

8.  Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Authors:  Klaus Koefoed; Lucilla Steinaa; Josefine Nielsen Søderberg; Ida Kjær; Helle Jane Jacobsen; Per-Johan Meijer; John Sørensen Haurum; Allan Jensen; Michael Kragh; Peter Sejer Andersen; Mikkel Wandahl Pedersen
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 9.  EGFR-targeted therapies in the post-genomic era.

Authors:  Mary Jue Xu; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

10.  Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells.

Authors:  Megan E Cavet; Elaine M Smolock; Oktay H Ozturk; Cameron World; Jinjiang Pang; Atsushi Konishi; Bradford C Berk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-21       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.